463 related articles for article (PubMed ID: 24738612)
1. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
[TBL] [Abstract][Full Text] [Related]
2. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.
Yi A; Cho N; Im SA; Chang JM; Kim SJ; Moon HG; Han W; Park IA; Noh DY; Moon WK
Radiology; 2013 Sep; 268(3):662-72. PubMed ID: 23592770
[TBL] [Abstract][Full Text] [Related]
4. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
Etxano J; Insausti LP; Elizalde A; López Vega JM; Plazaola A; Martínez P
Acta Radiol; 2015 Nov; 56(11):1300-7. PubMed ID: 25348477
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
7. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.
Li SP; Makris A; Beresford MJ; Taylor NJ; Ah-See ML; Stirling JJ; d'Arcy JA; Collins DJ; Kozarski R; Padhani AR
Radiology; 2011 Jul; 260(1):68-78. PubMed ID: 21502383
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
[TBL] [Abstract][Full Text] [Related]
9. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
Pickles MD; Lowry M; Manton DJ; Gibbs P; Turnbull LW
Breast Cancer Res Treat; 2005 May; 91(1):1-10. PubMed ID: 15868426
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
[TBL] [Abstract][Full Text] [Related]
11. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
[TBL] [Abstract][Full Text] [Related]
12. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
13. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results.
Padhani AR; Hayes C; Assersohn L; Powles T; Makris A; Suckling J; Leach MO; Husband JE
Radiology; 2006 May; 239(2):361-74. PubMed ID: 16543585
[TBL] [Abstract][Full Text] [Related]
14. Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer.
Kim Y; Kim SH; Song BJ; Kang BJ; Yim KI; Lee A; Nam Y
Korean J Radiol; 2018; 19(4):682-691. PubMed ID: 29962874
[TBL] [Abstract][Full Text] [Related]
15. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy.
Yu HJ; Chen JH; Mehta RS; Nalcioglu O; Su MY
J Magn Reson Imaging; 2007 Sep; 26(3):615-23. PubMed ID: 17729334
[TBL] [Abstract][Full Text] [Related]
16. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
17. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
Martincich L; Montemurro F; De Rosa G; Marra V; Ponzone R; Cirillo S; Gatti M; Biglia N; Sarotto I; Sismondi P; Regge D; Aglietta M
Breast Cancer Res Treat; 2004 Jan; 83(1):67-76. PubMed ID: 14997056
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
[TBL] [Abstract][Full Text] [Related]
19. Dynamic breast magnetic resonance imaging: pretreatment prediction of tumor response to neoadjuvant chemotherapy.
Dongfeng H; Daqing M; Erhu J
Clin Breast Cancer; 2012 Apr; 12(2):94-101. PubMed ID: 22169574
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
